Cellosaurus logo
expasy logo

Cellosaurus UACC-903 (CVCL_4052)

[Text version]
Cell line name UACC-903
Synonyms UACC 903; UACC903; University of Arizona Cell Culture-903
Accession CVCL_4052
Resource Identification Initiative To cite this cell line use: UACC-903 (RRID:CVCL_4052)
Comments Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Back; UBERON=UBERON_0001137.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9598804).
  • Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15009714).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Tyr76Ter (c.228T>G); ClinVar=VCV000546013; Zygosity=Unspecified (PubMed=9692547; PubMed=10766161; PubMed=15009714).
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 25Y
Category Cancer cell line
Publications

PubMed=2300817; DOI=10.1126/science.2300817
Trent J.M., Stanbridge E.J., McBride H.L., Meese E.U., Casey G., Araujo D.E., Witkowski C.M., Nagle R.B.
Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6.
Science 247:568-571(1990)

PubMed=2068080; DOI=10.1073/pnas.88.14.6028
Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)

PubMed=9692547; DOI=10.1038/sj.onc.1201881
Tsao H., Zhang X., Benoit E., Haluska F.G.
Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines.
Oncogene 16:3397-3402(1998)

PubMed=9823299
Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Cancer Res. 58:5009-5013(1998)

PubMed=9973934; DOI=10.1016/S0165-4608(98)00122-8
Nelson M.A., Ariza M.E., Yang J.-M., Thompson F.H., Taetle R., Trent J.M., Wymer J., Massey-Brown K.S., Broome-Powell M., Easton J., Lahti J.M., Kidd V.J.
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Cancer Genet. Cytogenet. 108:91-99(1999)

PubMed=10766161
Tsao H., Zhang X., Fowlkes K., Haluska F.G.
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Cancer Res. 60:1800-1804(2000)

PubMed=10952317; DOI=10.1038/35020115
Bittner M., Meltzer P.S., Chen Y.-D., Jiang Y., Seftor E.A., Hendrix M.J.C., Radmacher M.D., Simon R.M., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F.M., Gooden C., Lueders J., Glatfelter A., Pollock P.M., Carpten J.D., Gillanders E.M., Leja D., Dietrich K., Beaudry C., Berens M.E., Alberts D.S., Sondak V.K., Hayward N.K., Trent J.M.
Molecular classification of cutaneous malignant melanoma by gene expression profiling.
Nature 406:536-540(2000)

PubMed=12115485; DOI=10.1002/ijc.10422
Feng Y.-M., Shi J.-Q., Goldstein A.M., Tucker M.A., Nelson M.A.
Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families.
Int. J. Cancer 99:834-838(2002)

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=19383853; DOI=10.1158/1535-7163.MCT-08-1030
Su D.M., Zhang Q.-Y., Wang X.-X., He P., Zhu Y.-L.J., Zhao J.-X., Rennert O.M., Su Y.A.
Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy.
Mol. Cancer Ther. 8:1292-1304(2009)

PubMed=23039341; DOI=10.1186/1476-4598-11-75
Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J., Nomoto K., Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012)

PubMed=24879157; DOI=10.4161/auto.28594
Goodall M.L., Wang T., Martin K.R., Kortus M.G., Kauffman A.L., Trent J.M., Gately S., MacKeigan J.P.
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
Autophagy 10:1120-1136(2014)

Cross-references
Cell line databases/resources cancercelllines; CVCL_4052
Lonza; 39
Anatomy/cell type resources BTO; BTO:0005060
Chemistry resources ChEMBL-Cells; CHEMBL3307961
ChEMBL-Targets; CHEMBL612446
PubChem_Cell_line; CVCL_4052
Encyclopedic resources Wikidata; Q54973868
Polymorphism and mutation databases Cosmic; 706103
Cosmic; 888843
Cosmic; 897489
Cosmic; 905860
Cosmic; 1020269
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number24